Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Alligator Bioscience AB ( (SE:ATORX) ).
Alligator Bioscience announced that data from its OPTIMIZE-1 clinical trial will be presented at the 2025 ASCO Annual Meeting. This presentation highlights the potential of their CD40 agonist, mitazalimab, in combination with mFOLFIRINOX for untreated metastatic pancreatic cancer. The event is a key opportunity for Alligator to showcase its advancements in immuno-oncology and explore strategic collaborations, potentially impacting its market position and stakeholder interests.
More about Alligator Bioscience AB
Alligator Bioscience is a clinical-stage biotechnology company based in Lund, Sweden, specializing in the development of tumor-directed immuno-oncology antibody drugs. The company focuses on the CD40 receptor to enhance tumor-specific T cell priming and counteract the immunosuppressive tumor microenvironment. Its lead drug candidate, mitazalimab, is advancing towards Phase 3 development, with promising results in metastatic pancreatic cancer.
YTD Price Performance: -80.29%
Average Trading Volume: 212,041
Current Market Cap: SEK70.16M
Learn more about ATORX stock on TipRanks’ Stock Analysis page.